Literature DB >> 11281846

Recent advances in NMR: expanding its role in rational drug design.

R P Hicks1.   

Abstract

The technology of nuclear magnetic resonance spectroscopy continues to advance at a rapid pace. Recent improvements in gradient technology and the coupling of NMR to various chromatography methods will provide new opportunities in drug discovery. These opportunities include rapid high throughput screening to determine the receptor-bound conformations of small organic ligands. NMR coupled to liquid chromatography has opened a new door to the quantitative and qualitative analysis of complex mixtures including metabolites extracted from body fluids and extracts containing various natural products. This review will focus on the following four advances in NMR technology: 1) pulse-field gradient (PFG) NMR, 2) SAR (structure activity relationship) by NMR, 3) LC-NMR (liquid chromatography), and 4) application of membrane models for the study of neuropeptides. The information content available to medicinal chemists from each experiment will be discussed.

Mesh:

Substances:

Year:  2001        PMID: 11281846     DOI: 10.2174/0929867013373237

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  3 in total

1.  Number of solution states of bradykinin from ion mobility and mass spectrometry measurements.

Authors:  Nicholas A Pierson; Liuxi Chen; Stephen J Valentine; David H Russell; David E Clemmer
Journal:  J Am Chem Soc       Date:  2011-08-15       Impact factor: 15.419

Review 2.  Exploring biology with small organic molecules.

Authors:  Brent R Stockwell
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

3.  Comparison of Peptide Ion Conformers Arising from Non-Helical and Helical Peptides Using Ion Mobility Spectrometry and Gas-Phase Hydrogen/Deuterium Exchange.

Authors:  Ahmad Kiani Karanji; Mahdiar Khakinejad; Samaneh Ghassabi Kondalaji; Sandra N Majuta; Kushani Attanayake; Stephen J Valentine
Journal:  J Am Soc Mass Spectrom       Date:  2018-10-15       Impact factor: 3.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.